Pharma and biotech major Wockhardt has received US FDA nod to launch 25 mg, 50 mg, 100 mg, 200 mg and 300 mg extended release tablets of Lamotrigine, a drug used in the treatment of epilepsy. This is the generic name for the brand Lamictal XR.
The company will be launching the product immediately. The US market for the drug is pegged at $250 million.
Wockhardt will manufacture the extended release tablets at its Aurangabad facility. The technology for extended release tablets was developed in-house, the company said.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.